• LAST PRICE
    1.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 1.0000
  • Day Range
    ---
  • 52 Week Range
    Low 0.6000
    High 2.3000
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRAPH
Raphael Pharmaceutical Inc
18.1M
-6.4x
---
United StatesCUBT
Curative Biotechnology Inc
18.2M
-2.7x
---
United StatesXLO
Xilio Therapeutics Inc
17.6M
-0.4x
---
United StatesNERV
Minerva Neurosciences Inc
17.5M
-0.6x
---
United StatesPPBT
Purple Biotech Ltd
17.1M
-0.8x
---
United StatesGDTC
CytoMed Therapeutics Ltd
25.8M
-5.5x
---
As of 2024-03-28

Company Information

Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. It is engaged in developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to Covid-19, or Covid-19 product candidate, which may be based on data or studies related to RA product candidate. It uses CBD oil as the active pharmaceutical ingredient (API), for its RA and COVID-19 product candidate.

Contact Information

Headquarters
SUITE 105 - 5348 VEGAS DR.LAS VEGAS, NV, United States 89108
Phone
702-442-1166
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Shlomi Pilo
Chief Financial Officer, General Counsel, Director
Guy Ofir
Chief Technology Officer, Chief Scientist, Director of the Scientific Advisory Board
Igal Louria-hayon
Advocate Accountant Internal Auditor Certified Salary, Mediator and Director
Yehuda Eliya
Scientific Advisory Board Member
Shai Izraeli

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.1M
Revenue (TTM)
$0.00
Shares Outstanding
18.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.16
Book Value
$0.01
P/E Ratio
-6.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.